DT-101 for adults with recurrent major depressive disorder
Official title: A Phase 2 Double-blind, Randomised, Placebo-controlled Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of DT-101 in Adults With Major Depressive Disorder (MDD)
Run by Draig Therapeutics Ltd · NCT07300969 · Data updated 2026-11-12
This trial will test whether DT-101 helps adults with recurrent major depressive disorder compared with a placebo.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Enrollment | 300 (estimated) |
| Sponsor | Draig Therapeutics Ltd Industry-sponsored |
| Locations | 43 sites (Bentonville, Arkansas and 42 other locations) |
| Status | Recruiting |
| Started | December 16, 2025 |
| Main results expected | August 2027 |
| Study ends | August 2027 |
| Registry record updated | October 8, 2026 |
| Trial ID | NCT07300969 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 18 to 75 with recurrent major depressive disorder who can consent, attend regular clinic visits, and do not have exclusionary medical, neurological, pregnancy, seizure, or recent substance-use conditions are ideal candidates.
✕Probably not a fit
People who are pregnant or breastfeeding, have unstable medical or neurological conditions, a history of seizures, recent moderate-to-severe substance use disorder, or who cannot adhere to study visits are unlikely to benefit from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This randomized, placebo-controlled Phase 2 trial enrolls adults with recurrent major depressive disorder to compare DT-101 against placebo. Participants visit the clinic every few weeks for health checks, symptom questionnaires, and safety monitoring. Blood and urine samples will be collected for standard safety labs, pharmacokinetic (PK) testing, and optional pharmacogenetic (PGx) research. The study excludes people who are pregnant or breastfeeding, have unstable medical or neurological conditions, recent substance use disorders, or a history of seizures.
Why it matters
Potential benefit: If successful, DT-101 could reduce depression symptoms and improve daily functioning for adults with recurrent MDD.
How similar studies have gone: DT-101 is an investigational agent and randomized, placebo-controlled Phase 2 trials of novel antidepressants have shown mixed results in the past, so this approach is common but not guaranteed to succeed.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * The participant is able to read, understand and communicate in the local language used at the study site, and is willing to provide written informed consent * Male or female (assigned at birth, inclusive of all gender identities) participant must be 18 to 75 years of age, inclusive at the time of signing the informed consent. * Has recurrent depression (defined as at least one prior episode excluding the current one), as diagnosed by DSM 5-TR (Diagnostic and Statistical Manual of Mental Disorders, 2022). Exclusion Criteria: * Pregnant or breastfeeding or plans to become pregnant during the study. * Unstable medical condition or unstable chronic disease. * Significant neurological abnormality. * History of moderate or severe alcohol or drug use disorder as per DSM-5-TR in the 6 months prior to Screening. * History of seizure. * In the investigator's opinion, the participant is not capable of adhering to the protocol requirements.
Where it's running
-
Draig Clinical Site
Bentonville, Arkansas, United States Recruiting -
Draig Clinical Site
Little Rock, Arkansas, United States Recruiting -
Draig Clinical Site
Oceanside, California, United States Recruiting -
Draig Clinical Site
San Diego, California, United States Recruiting -
Draig Clinical Site
Torrance, California, United States Recruiting -
Draig Clinical Site
Miami, Florida, United States Recruiting
Show 37 more locations
-
Draig Clinical Site
Orlando, Florida, United States Recruiting -
Draig Clinical Site
Atlanta, Georgia, United States Recruiting -
Draig Clinical Site
Decatur, Georgia, United States Recruiting -
Draig Clinical Site
Gaithersburg, Maryland, United States Recruiting -
Draig Clinical Site
Watertown, Massachusetts, United States Recruiting -
Draig Clinical Site
Flowood, Mississippi, United States Recruiting -
Draig Clinical Site
Las Vegas, Nevada, United States Recruiting -
Draig Clinical Site
Marlton, New Jersey, United States Recruiting -
Draig Clinical Site
New York, New York, United States Recruiting -
Draig Clinical Site
Austin, Texas, United States Recruiting -
Draig Clinical Site
Austin, Texas, United States Recruiting -
Draig Clinical Site
DeSoto, Texas, United States Recruiting -
Draig Clinical Site
Richardson, Texas, United States Recruiting -
Draig Clinical Site
Bellevue, Washington, United States Recruiting -
Draig Clinical Site
Kazanlak, Bulgaria Recruiting -
Draig Clinical Site
Plovdiv, Bulgaria Recruiting -
Draig Clinical Site
Sofia, Bulgaria Recruiting -
Draig Clinical Site
Sofia, Bulgaria Recruiting -
Draig Clinical Site
Sofia, Bulgaria Recruiting -
Draig Clinical Site
Sofia, Bulgaria Recruiting -
Draig Clinical Site
Vratsa, Bulgaria Recruiting -
Draig Clinical Site
Ostrava, Czechia Recruiting -
Draig Clinical Site
Prague, Czechia Recruiting -
Draig Clinical Site
Říčany, Czechia Recruiting -
Draig Clinical Site
Gdansk, Poland Recruiting -
Draig Clinical Site
Katowice, Poland Recruiting -
Draig Clinical Site
Poznan, Poland Recruiting -
Draig Clinical Site
Chester, United Kingdom Recruiting -
Draig Clinical Site
Eastbourne, United Kingdom Recruiting -
Draig Clinical Site
Glasgow, United Kingdom Recruiting -
Draig Clinical Site
London, United Kingdom Recruiting -
Draig Clinical Site
London, United Kingdom Recruiting -
Draig Clinical Site
Nottingham, United Kingdom Recruiting -
Draig Clinical Site
Oxford, United Kingdom Recruiting -
Draig Clinical Site
New Port Richey, Florida, United States Terminated -
Draig Clinical Site
Media, Pennsylvania, United States Terminated -
Draig Clinical Site
Wichita Falls, Texas, United States Terminated
Study contacts
- Study coordinator: Chief Medical Officer
- Email: info@draigtherapeutics.com
- Phone: +44(0)2920028450
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Emotional Reactivity in Severe Alcohol Use Disorder and Depression Using Eye-Tracking and Physiological Measures
This study tests how people with severe alcohol use disorder, major depressive disorder, both conditions, or neither, recognize and react to emotions using eye-tracking and physiological data.
-
Temporally Interfering Electrical Stimulation for Major Depressive Disorder
This study tests whether noninvasive temporally interfering electrical stimulation can help people with major depressive disorder.
-
Affective Cognitive Training for mood disorders and their close relatives
A six-week program combining virtual reality and computer exercises tests whether affective cognitive training helps people with mood disorders and their unaffected first-degree relatives.
-
ALKS 7290 added to antidepressants for adults with major depression
This study tests whether ALKS 7290, taken with current antidepressants, helps adults with major depressive disorder.
-
French Minds: a French, Multimodal Cohort Study of Severe Psychiatric Disorders and Healthy Controls
This study tests whether people with mood, psychotic, or autism disorders can be grouped into more similar subtypes based on social withdrawal and anhedonia, across ages 15 to 60.
-
EEG-Guided TMS for Adults With Depression
This study tests whether delivering intermittent theta burst stimulation (iTBS) timed to brain waves using EEG can improve treatment for adults with major depressive disorder who have not responded to usual antidepressants.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.